Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma × olaparib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 41 Breast Neoplasms 34 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Neoplasms 11 Fallopian Tube Neoplasms 10 Endometrial Neoplasms 10 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Recurrence 7 Neoplasm Metastasis 5 Carcinoma, Ovarian Epithelial 5 Sarcoma 4 Lung Neoplasms 4 Glioma 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Solid Tumor 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Carcinoma, Non-Small-Cell Lung 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Neuroendocrine Tumors 2

Interventions

Cyclophosphamide 272 Rituximab 243 Etoposide 136 Filgrastim 128 fludarabine phosphate 105 Cytarabine 98 Vincristine 97 Radiotherapy 96 Melphalan 95 Doxorubicin 90 Peripheral Blood Stem Cell Transplantation 82 Methotrexate 80 fludarabine 78 Prednisone 78 Busulfan 77 Tacrolimus 54 Whole-Body Irradiation 52 Mycophenolic Acid 52 Granulocyte Colony-Stimulating Factor 52 Dexamethasone 52 Antilymphocyte Serum 51 Carmustine 49 Cyclosporine 39 Lenalidomide 38 Methylprednisolone 37 Bortezomib 37 Bendamustine Hydrochloride 34 sargramostim 33 Stem Cell Transplantation 31 Ifosfamide 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03575078 2019-09-25

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

University of Texas Southwestern Medical Center

Phase 1 Withdrawn

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡